OKYO Pharma Appoints MD PhD Expert, Secures Fast Track for 150-Patient Phase 2b/3
OKYO Pharma expanded its Scientific Advisory Board with Marta Sacchetti, MD, PhD, bolstering expertise in neuro-inflammatory corneal disease and targeted nerve regeneration. The company’s urcosimod holds the first IND for neuropathic corneal pain plus FDA Fast Track designation and will launch a 150-patient Phase 2b/3 study in H1 2026.
1. Scientific Advisory Board Expansion
OKYO Pharma has appointed Marta Sacchetti, MD, PhD, to its Scientific Advisory Board, enhancing its global network of corneal disease specialists. Dr. Sacchetti’s roles as Associate Professor of Ophthalmology at Link University and former Global Head of Clinical Development at Dompé Farmaceutici provide deep expertise in neuro-inflammatory corneal conditions and nerve regeneration.
2. Urcosimod Development Milestones
Urcosimod is the first investigational therapy with an IND specifically for neuropathic corneal pain and has received FDA Fast Track designation. Following positive Phase 2 pain-reduction data, OKYO plans to initiate a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026 to advance global clinical development.